Skip to main content
SpringerLink
Log in

Treatment strategy for IgA nephropathy depends on the risk of disease progression

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rostoker G. Therapy of IgA nephropathy. BioDrugs 1998 Apr; 9(4): 279–301

    Article  PubMed  CAS  Google Scholar 

  2. Ibels LS, Gyory AZ, Caterson RJ, et al. Recognition and management of IgA nephropathy. Drugs 1998 Jan; 55(1): 73–83

    Article  PubMed  CAS  Google Scholar 

  3. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 1994; 73: 79–102

    Article  PubMed  CAS  Google Scholar 

  4. Clarkson A, Woodroffe A, Bannister K, et al. The syndrome of IgA nephropathy. Clin Nephrol 1984; 21: 7–14

    PubMed  CAS  Google Scholar 

  5. Ibels LS, Gyory AZ, Caterson RJ, et al. Primary IgA nephropathy natural history and factors of importance in the progression of renal impairment. Kidney Int. In press

  6. Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplant 1995; 10 Suppl. 9: 46–51

    PubMed  Google Scholar 

  7. Jacobson HR, Stricker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 1995; 25: 103–6

    Article  PubMed  CAS  Google Scholar 

  8. Bedogna V, Valvo E, Casagrande P, et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38: 101–7

    Article  PubMed  CAS  Google Scholar 

  9. Donadio Jr JV, Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194–9

    Article  PubMed  Google Scholar 

  10. Lagrue G, Sadreux T, Laurent J, et al. Is there a treatment of mesangial IgA glomerulonephritis [letter]? Clin Nephrol 1980; 14: 161

    Google Scholar 

  11. Galla J. IgA nephropathy. Kidney Int 1995; 47: 377–87

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Treatment strategy for IgA nephropathy depends on the risk of disease progression. Drugs Ther. Perspect 13, 5–8 (1999). https://doi.org/10.2165/00042310-199913010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913010-00002

Keywords

Search

Navigation